AXIM (AXIM Biotechnologies) Total Liabilities: $13.65 Mil (As of Jun. 2025)


What is AXIM Biotechnologies Total Liabilities?

AXIM Biotechnologies AXIM Total Liabilities is $13.65 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

AXIM Biotechnologies's Total Liabilities for the quarter that ended in Jun. 2025 was $13.65 Mil.

AXIM Biotechnologies's quarterly Total Liabilities increased from Dec. 2024 ($13.87 Mil) to Mar. 2025 ($13.98 Mil) but then declined from Mar. 2025 ($13.98 Mil) to Jun. 2025 ($13.65 Mil).

AXIM Biotechnologies's annual Total Liabilities increased from Dec. 2022 ($9.04 Mil) to Dec. 2023 ($11.78 Mil) and increased from Dec. 2023 ($11.78 Mil) to Dec. 2024 ($13.87 Mil).

AXIM Biotechnologies Total Liabilities Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Total Liabilities Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.75 7.66 9.04 11.78 13.87

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.38 13.26 13.87 13.98 13.65

AXIM Biotechnologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AXIM Biotechnologies's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.762+(7.104+0.0010000000000012
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.87

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=3.447--10.42
=13.87

AXIM Biotechnologies's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.206+(7.444+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.65

Total Liabilities=Total Assets (Q: Jun. 2025 )-Total Equity (Q: Jun. 2025 )
=3.224--10.426
=13.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $13.65 Mil mean?
AXIM Biotechnologies (AXIM) has a Total Liabilities of $13.65 Mil as of Jun. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Total Liabilities too high?
AXIM Biotechnologies' current Total Liabilities is $13.65 Mil.
How does AXIM Biotechnologies' Total Liabilities compare to HEPA and SCNI?
AXIM Biotechnologies' Total Liabilities of $13.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Total Liabilities is $13.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Total Liabilities of $13.65 Mil. The current Total Liabilities is $13.65 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Total Liabilities is $13.65 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.